Navigation Links
Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
Date:9/30/2009

TCA 650 on day 1 and removal on day 29.

    Fasting & Postprandial Glucose  ITCA 650 Dose Arms (continuous daily dose)
                                    ------------------------------------------
                                     10          20          40         80
                                   mcg/day     mcg/day     mcg/day    mcg/day
    --------------------------------------------------------------------------
    Mean FPG at baseline (mg/dL)     161.2       170.5       171.8      145.1
    --------------------------------------------------------------------------
    Mean FPG at end of
     treatment (mg/dL)               155.6       139.4       129.8      116.3
    --------------------------------------------------------------------------
    Change from baseline (mg/dL)      -5.6       -31.1*      -42.0*     -28.8*
    --------------------------------------------------------------------------
    Change in 2-hr PPG at end
     of treatment (mg/dL)            -16.3       -34.7*      -47.1*     -69.6*
    --------------------------------------------------------------------------
    *p = < 0.05

Substantial decreases in FPG and PPG were observed throughout treatment. Decreases in FPG were evident within 24 hours after initiation of treatment, suggesting a rapid and consistent achievement of desired exenatide levels with DUROS delivery. Changes in PPG measured at days 15 and 29 also showed consistent dose-dependent reductions. Changes from baseline in FPG and PPG were statistically significant for the 20 mcg/day, 40 mcg/day and 80 mcg/day doses.

    HbA1c & Body Weight             ITCA 650 Dose Arms (continuous daily dose)
                                    ------------------------------------------
                                     10          20          40        80
                                   mcg/day     mcg/day     mcg/day   mcg/day
    ----------------------------------------------------
'/>"/>
SOURCE Intarcia Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
2. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
3. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
4. Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes
5. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
6. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
7. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
8. Nile Therapeutics, Inc. Adds to Executive Management Team
9. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
10. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
11. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Jan. 22, 2015   GenoSpace , a precision medicine software ... enable the broad use of genomic, imaging and other biomedical ... of Michelle Munson , CEO of Aspera, an IBM ... Logo - http://photos.prnewswire.com/prnh/20150122/170713 "We are ...
(Date:12/24/2014)... and NEW YORK , Dec. 24, ... company advancing patient care in critical areas, announced the closing ... stock, and warrants to purchase up to an aggregate 3,500,000 ... per share and $.01 per warrant.  The warrants have a ...
(Date:12/24/2014)... Missouri (PRWEB) December 23, 2014 GMO corn ... company, Syngenta, are in the process of being consolidated in ... is In Re: Syngenta AG MIR 162 Corn Litigation, MDL ... of Kansas. , Management of the Syngenta GMO corn multidistrict ...
(Date:12/24/2014)... Long Island, New York (PRWEB) December 23, 2014 ... , and the Long Island Affiliate of ITRA Global, the ... economy’s slow but steady recovery. This is evidenced by ... and the strong stock market. Low energy costs have ...
Breaking Biology Technology:GenoSpace Expands Board with Appointment of Michelle Munson 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3
... State spending on information technology may soon be subject ... costing tens of millions of dollars each, have failed ... and representative Suzanne Jeskewitz, co-chairs of the Joint Audit ... developed or renovated recently are inefficient or non-functional, and ...
... citywide wireless network in Milwaukee, the surrounding communities of ... , ,Waukesha and Wauwatosa are already being pitched by ... the city of Madison. Milwaukee's network is being built ... the deals established so far, the city is essentially ...
... At $2.5 million per 30-second spot, the average 2006 ... TV advertising has never been more affordable for small ... Spot Runner , it's possible to implement a comprehensive ... at a fraction of the normal cost. You can ...
Cached Biology Technology:Local TV advertising - Super Bowl vs. super bargain 2Local TV advertising - Super Bowl vs. super bargain 3Local TV advertising - Super Bowl vs. super bargain 4
(Date:12/11/2014)... blood pressure plays a role in human health has been ... for high blood pressure – was first described as a ... used in measuring blood pressure was invented in 1896. ... its triggers and its effects. In fact, recent findings have ...
(Date:12/10/2014)... , Dec. 8, 2014 You,ve been here before: you ... remember your password, site key or the answer to your secret ... Today, Hoyos Labs , a digital infrastructure ... an end to the frustration that comes with usernames, passwords and ...
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical Center ... its School of Medicine. Funding for this $50 million capital ... be publicly launched next summer. The medical ... R.J. Reynolds Tobacco Company complex, adjacent to 525@vine in Wake ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... , RENO, Nev. A novel treatment in development at ... common form of muscular dystrophy is advancing towards human trials ... The grant will be used to expand successful research by ... laminin-111 protein therapy prevents the onset of the devastating neuromuscular ...
... the strongest materials on Earth and are used to strengthen ... CNTs have potential uses in everything from medicine to electronics ... study by the University of Missouri and United States Geological ... The researchers urge that care be taken to prevent the ...
... AMES, Iowa Edward Yu took note of the facts ... each year, developments of multidrug-resistant, extensively drug-resistant and now totally ... to tuberculosis. Yu, an Iowa State University and Ames ... the three-part structure that allows E. coli bacteria ...
Cached Biology News:MDA supports Duchenne muscular dystrophy research by University of Nevada School of Medicine 2MDA supports Duchenne muscular dystrophy research by University of Nevada School of Medicine 3Iowa State, Ames Lab researchers study the structure of drug resistance in tuberculosis 2Iowa State, Ames Lab researchers study the structure of drug resistance in tuberculosis 3
...
Full-length cDNA clone CS0DJ013YG01 of T cells (Jurkat cell line) of Homo sapiens (human). [Source:Uniprot/SPTREMBL;Acc:Q86SZ3] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
...
...
Biology Products: